Biolab's first Sustainability Report highlights the company's attention to people and management.
Commitment to employees has always been a priority at Biolab Farmacêutica. From January to December 2023, the company invested even more in diversity programs, attracting and retaining talent, professional development and health and well-being. The initiatives were aimed at promoting an inclusive, safe and positive work environment, ensuring the continuous development of employees and strengthening the organizational culture.
These and other company actions can be found in Biolab's first Annual Sustainability Report, which has just been presented to the market. The publication presents a comprehensive overview of the company's main achievements, challenges and commitments in relation to ESG issues - environmental, social and governance responsibility. "Our first Biolab Annual Sustainability Report reflects the company's transparency in its actions and, even though it is not mandatory, we feel it is our duty to disclose and record our sustainable practices, highlighting our ongoing commitment to sustainable development and responsible innovation," says Cleiton de Castro Marques, a member of Biolab Farmacêutica's board of directors.
The company undertook a careful process with the support of a specialized consultancy to identify and prioritize the most relevant sustainability issues for the organization and its stakeholders. The process was guided by a robust methodology, which included sector benchmark analysis, evaluation of internal documents, sustainability indexes and consultation with various groups. This process made it possible to clearly define the issues that most impact the company and its value chain.
"The 2023 Sustainability Report reaffirms Biolab's commitment to ethics, innovation and sustainable growth based on the values of commitment, adaptability, entrepreneurship and valuing people. The initiatives reported demonstrate our efforts to reconcile economic development with social and environmental responsibility, always guided by solid and transparent governance," says Tati Marques, Director of Corporate Communication and Sustainability at Biolab Farmacêutica.
Central themes - Twelve themes have been prioritized by Biolab and will guide its actions in 2023. They are: Ethics and Compliance; Corporate Governance and Transparency; Product Launches, Research, Development and Innovation; Product Quality and Safety; Capacity and Industrial Planning; Risk Management; Customer Relations and Satisfaction; Data Intelligence; Relations with Doctors; People Management; Social Responsibility and Environmental Management. These themes reflect Biolab's commitment to innovation, sustainable development and ethical and transparent relations with its stakeholders.
"Biolab faced commercial and industrial challenges, but overcame them with robust planning, ending the year with positive results. We achieved gross revenue of R$ 2.4 billion in Brazil, with an EBITDA margin of 22%, reflecting growth and financial efficiency. All of these results were achieved through the solid pillars of Governance, sustainability and social responsibility that permeate our business model," said Cleiton Marques.
To see the sustainability report, go to https://www.biolabfarma.com.br/.
About Biolab
Promoting a future with a better quality of life requires a tireless search for safe and innovative treatments. With this mission in mind, Biolab, a Brazilian pharmaceutical company founded in 1997 and with an international presence, invests in research and partnerships to overcome the growing challenges of health.
With more than 4,000 employees and the 4th largest sales force in Brazil, Biolab is among the largest pharmaceutical companies in the country, operating in various specialties, such as dermatology, gynecology, orthopedics, gastroenterology, pediatrics, clinical medicine and central nervous system, as well as being a leader in cardiology. The business units Biolab Generic, Avert Humana e Avert Biolab Animal Health contribute with a portfolio of more than 500 products.
Biolab is constantly growing. It has three production units, as well as a modern manufacturing complex under construction. And it doesn't stop there: in Canada it is the first Brazilian pharmaceutical company with a Research Center and it acquired the company Exzell Pharma to expand its borders.
Long live evolution!
Find out more at www.biolabfarma.com.br and on social media: Instagram, Facebook and Linkedin